Podcasts about Genoa

Cane weaponizes Billy; Jack pulls the AC funding; Sally stands by her man; Whose side is Phyllis on?; Claire finds out about Kyle’s contract with Victor; Holden defends Claire; and Mariah TRIED to kill a man. PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The Chatterbox” to Read YOUR Comments! Sign […]

This week on The Trawl, Jemma and Marina steer through a week where compassion and chaos collided.From the flotilla of medics, activists and even Greta Thunberg, risking everything to get aid into Gaza, to dockworkers in Genoa refusing to load arms shipments, there are still flashes of humanity in the darkest of times. Hugh Bonneville's rallying cry, businesses putting morals above profit, and ordinary people prepared to be arrested for protesting against genocide — proof that not everyone in the world is a hideous f@%kwit.But alas, back home… Labour descends into turmoil with Rayner out and reshuffle chaos in. Clive Lewis nails why so many think “they're all the same,” while Jemma and Marina discuss how her departure from the upper echelons of cabinet makes them feel. Meanwhile, Farage is busy lecturing Rayner on tax only to get exposed for his own questionable dealings. Quelle surprise.And then there's the Reform Party Conference. Andrea Jenkyns makes an entrance that has to be seen to be believed and heard to be horrified. Femi reminds us why the “clowns” are more dangerous than they look, and Paul Mason swoons over the lot of them. Spoiler: it's terrifyingThe Trawl ladies wrap up with Under Rated's and a Larry & Paul pudding to cleanse your palate.The good, the bad, the ludicrous — it's all in this episode of The Trawl.Thank you for sharing and do tweet us @MarinaPurkiss @jemmaforte @TheTrawlPodcast Patreonhttps://patreon.com/TheTrawlPodcast Youtubehttps://www.youtube.com/@TheTrawl Twitterhttps://twitter.com/TheTrawlPodcastIf you've even mildly enjoyed The Trawl, you'll love the unfiltered, no-holds-barred extras from Jemma & Marina over on Patreon, including:• Exclusive episodes of The Trawl Goss – where Jemma and Marina spill backstage gossip, dive into their personal lives, and often forget the mic is on• Early access to The Trawl Meets…• Glorious ad-free episodesPlus, there's a bell-free community of over 3,300 legends sparking brilliant chat.And it's your way to support the pod which the ladies pour their hearts, souls (and occasional anxiety) into. All for your listening pleasure and reassurance that through this geopolitical s**tstorm… you're not alone.Come join the fun:https://www.patreon.com/TheTrawlPodcast?utm_campaign=creatorshare_creator Hosted on Acast. See acast.com/privacy for more information.

Finita la pausa nazionali, tra oggi e domani il Genoa serrerà i ranghi in vista di Como. Analizziamo la situazione, con Vieira che oggi ha accolto il Presidente Sucu a Pegli. Spazio anche a tutti gli impegni del weekend tra Genoa Women e giovanili. Buoncalcioatutti!

Il Genoa riprende gli allenamenti e riabbraccia Grønbæk, il primo nazionale a fare rientro alla base. Oggi tanti impegni per i calciatori rossoblù, attesi a Genova tra domani e al più tardi venerdì. Intanto, maggiori info sui biglietti di Como e Bologna. Buoncalcioatutti!

Click to Subscribe: https://bit.ly/Youtube-Subscribe-SoapDirt Young and the Restless spoilers this week focus on Victor Newman (Eric Braeden), Claire Newman (Hayley Erin), Kyle Abbott (Michael Mealor), and Audra Charles (Zuleyka Silver). The plot thickens as Claire grapples with her feelings about Kyle's actions and a secret deal with Victor. Audra, on the other hand, continues to cause trouble, much to the concern of Victoria Newman (Amelia Heinle), and Sally Spectra (Courtney Hope). Y&R spoilers reveal that Victor Newman comforts his granddaughter Claire Newman when she's upset about Kyle Abbott's deception, and reveals that Kyle had passed his test. However, Victor's refusal to disclose the details of a mysterious deal with Kyle stirs further confusion and tension. Kyle struggles to explain his actions and the deal with Victor, while dealing with the fallout of his ill-timed marriage proposal. Victoria Newman and Kyle worry about the ongoing threat posed by Audra Charles, and Victor and Victoria agree that Audra should leave Genoa city. More weekly spoilers for The Young and the Restless indicate that Audra Charles is advised by Sally Spectra to maintain her best behavior at the Abbott com launch party. Despite this, Audra continues to stir trouble, which worries Sally and Billy Abbott (Jason Thompson). Audra's actions in LA are also revealed, leading to a tense encounter with Holden Novak (Nathan Owens) who warns her to leave Claire and Kyle alone.  And more spoilers for Y&R hint that Mariah Copeland (Camryn Grimes) makes a confession, and Phyllis Summers (Michelle Stafford) gets a warning from Nick Newman (Joshua Morrow) about Cane Ashby's (Billy Flynn) new project. The week wraps up with Sally facing an ethical problem and Cane gaining a new ally. Casting news reveals the addition of Matt Cohen as Detective Burroughs. The Soap Dirt podcast made the Top 100 List for Apple Podcast's Entertainment News Category. Visit our Young and the Restless section of Soap Dirt: https://soapdirt.com/category/young-and-the-restless/ Listen to our Podcasts: https://soapdirt.podbean.com/ And Check out our always up-to-date Young and the Restless Spoilers page at: https://soapdirt.com/young-and-the-restless-spoilers/ Check Out our Social Media... Twitter: https://twitter.com/SoapDirtTV Facebook: https://www.facebook.com/SoapDirt Pinterest: https://www.pinterest.com/soapdirt/ TikTok: https://www.tiktok.com/@soapdirt Instagram: https://www.instagram.com/soapdirt/

Anche se gli allenamenti riprenderanno domani, si apre la settimana che porterà a Como-Genoa, sfida valida per la terza giornata di campionato. Nel frattempo, in campo i nazionali, esordio positivo per l'Under 18 e pareggio con indicazioni preziose per il Genoa Women nel secondo turno di Serie A Women's Cup. Ne parliamo in puntata. Buoncalcioatutti!

Victor wants Cane’s AI; Nikki reverses the romance; Claire turns down Kyle’s marriage proposal; Holden ’em back; Audra comes clean with Nate; and Sally accepts Billy’s moving in proposal. PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The Chatterbox” to Read YOUR Comments! Sign up to receive private e-mail updates from […]

Episode 353 of RevolutionZ examines two seemingly unrelated but equally disruptive forces: the marginalization of participatory economics and the existential threat of artificial intelligence. But first, a visit to Genoa's dockworkers threatening to shut down Israel shipments, America's sex trafficking being addressed incompletely, and activist self censoring doing Trump's work for him.On the headline topics, for over five decades, a persistent but small bunch have advocated for participatory economics—a vision that rejects the inequitable remuneration, authoritarian decision-making, corporate division of labor, central planning and markets and proposes in their place equitable remuneration, self management, balanced job complexes and participatory planning. The topic, why does this vision remain largely ignored by mainstream leftist discourse. Is the silence merely the natural skepticism that greets any new idea, or does it reflect something deeper—perhaps even the uncomfortable truth that many progressive institutions themselves maintain the very power structures participatory economics challenges?On topic two, while many progressives dismiss AI as "just another tool" or even "a bad joke," this episode notes its unprecedented development trajectory. From barely performing elementary math to solving complex problems better than humans, from blather to eloquence, AI's capabilities are expanding exponentially. The threats are multifaceted: mass job displacement, potential rogue behavior, use for surveillance and repression, ecological damage from energy consumption, and the gradual replacement of uniquely human activities that give our lives meaning.Both participatory economics and AI concerns represent fundamental challenges to established power structures and conventional thinking. The resistance to engaging seriously with either topic stems from a combination of vested interests, habitual thinking, and perhaps a fear of considering truly revolutionary change. By bringing these issues into conversation, the episode invites us to reconsider blind spots and imagine alternative futures where economic systems serve human flourishing rather than perpetuating hierarchy.How might our economic vision change if we truly embraced participatory principles? What guardrails must we establish around AI before its development outpaces our ability to control it? These questions demand urgent attention as we navigate our agendas in increasingly confusing times.Support the show

Ralph welcomes Palestinian-American writer, activist, and scientist Susan Abulhawa to discuss the ongoing Palestinian genocide and the evidence that supports a vastly higher death toll in Gaza.Susan Abulhawa is a Palestinian-American writer and political activist. She is the author of Mornings in Jenin—translated into thirty languages—and The Blue Between Sky and Water. Born to refugees of the Six Day War of 1967, she moved to the United States as a teenager, graduated in biomedical science, and established a career in medical science. In July 2001, she founded “Playgrounds for Palestine,” a non-governmental children's organization dedicated to upholding the Right to Play for Palestinian children.I consider this, first of all, immoral. It's disrespecting the Palestinian dead while they kill the Palestinians who are still alive with US bombers and artillery shells and other weapons coming from Washington, D.C. And it underestimates the kind of urgency that should be confronting this genocide.Ralph NaderThis is something that I think generations will study for a very long time to come. The complicity of Western media across the board is no less criminal than the genocide itself.Susan AbulhawaThis is a complete wiping out of life. A total destruction. And it's completely driven by this unfathomable hate and colonial arrogance and Jewish supremacy and this notion of entitlement. Of being favored by God, of being promised some real estate by a real-estate-agent Lord. I mean, it beggars belief the narratives that we see spoken in mainstream outlets and in the halls of power. Truly, it beggars belief.Susan AbulhawaNo, I don't believe Israel has a right to exist. It has never had a right to exist. No political entities have a right to exist. People have a right to exist. They have a right to exist in their own homeland with dignity. People have a right to universal dignity. A supremacist ideology—and that's ultimately what Zionism is predicated on, on supremacy and entitlement for a group of people at the detriment of another group of people—that is not a right, and it should never be a right. It should be anathema, in fact.Susan AbulhawaNews 9/5/25* The Intercept reports AIPAC has lost another Democratic ally in Congress. Congresswoman Deborah Ross of North Carolina has pledged that she will not accept AIPAC campaign contributions in her 2026 reelection bid. In previous elections, Ross has accepted over $100,000 in AIPAC donations. This comes on the heels of another North Carolina Congresswoman, Valerie Foushee – who received over $800,000 in AIPAC contributions – also renouncing donations from the group. As the Intercept notes, in June, the North Carolina Democratic Party adopted a resolution calling for a “complete arms embargo on all military aid to Israel until it ends its apartheid rule of Palestinians.” Dr. Paul McAllister, a reverend and chair of the Interfaith Caucus of the North Carolina Democratic Party, is quoted saying “AIPAC uses the muscle of their resources to oust anyone who disagrees with them regarding Israel, the conduct of Israel and the atrocities that may be committed by the government of Israel — so it is good that Deborah Ross is willing to recognize and acknowledge that.”* In more Israel news, a new aid flotilla bound for Gaza departed from Genoa, Italy last Sunday. Unlike previous flotillas however, this one carries the protection of a surprising group: Italian dockworkers. According to POLITICO EU, “Speaking at a rally on the docks of Genoa, one of Europe's largest ports, a dockworker representing the USB union said…‘Around mid-September, these boats will arrive near the coast of Gaza. If we lose contact with our boats, with our comrades, even for just 20 minutes, we will shut down all of Europe.'” Genoa has expressed unprecedented solidarity with Gaza. A food drive in the city collected “more than 300 tons of humanitarian aid…[and] over 40,000 people, including the city's mayor, Silvia Salis, joined a torchlit march through the streets in support of the [humanitarian flotilla on Saturday].” During the procession, Salis remarked “Every day I am proud to be the mayor of this city, but tonight, if possible, I am even more so.”* In yet another Israel story, Tom Artiom Alexandrovich, an Israeli cybersecurity apparatchik, who was arrested in August during an undercover operation “targeting child sex predators,” failed to appear for his court date in Nevada. Alexandrovich fled to Israel after being bailed out of jail in the U.S.; his lawyer, David Chesnoff, told the court that he told Alexandrovich not to attend the hearing. Judge Barbara Schifalacqua is now demanding that Alexandrovich appear before the court this week, but it remains to be seen whether he will actually show. This case has become politicized, with liberals and conservatives accusing one another of allowing Alexandrovich to flee the country. The government of Israeli Prime Minister Benjamin Netanyahu falsely denied that Alexandrovich was arrested at all. This from Al Jazeera.* In more sex predator news, Representatives Ro Khanna, Thomas Massie and Marjorie Taylor-Greene held a press conference this week with survivors of abuse at the hands of Jeffrey Epstein to push for full disclosure of the Justice Department's files on the case. At this conference, survivors also said they will release their own list of names. This comes amidst a renewed push for Congressional action spearheaded by the survivors. On Tuesday, the House Oversight Committee released a batch of records, but most of these have been made public before. The survivors met with lawmakers this week, including Speaker Mike Johnson, who said “I think the Oversight probe is going to be wide and expansive, and they're going to follow the truth wherever it leads,” per the Washington Post. Congresswoman Nancy Mace was also seen emerging from a meeting with the survivors visibly upset, though we do not know what exactly was discussed in this meeting. What is clear is that the Epstein story is not going away any time soon.* In local news, the National Guard has shared a statement with CBS News' Scott MacFarlane in which they boast that, “Guardsmen have cleaned more than 3.2 miles of roadways, collected more than 500 bags of trash, and disposed of three truckloads of plant waste.” Looking beyond the absurdity of deploying the National Guard to pick up trash, Samuel Littauer, Commissioner of ANC 3C01 – a local government district in Washington – crunched the numbers and found that “DC's cleaning crews cover around 81 miles/day for around $150K/day… [while the] National Guard has cleaned a total of 3.2 miles and costs more than $1M/day.” This means, “It's about 170X more cost efficient per mile to fund DC's existing work.”* Yet, despite the staggering inefficiency of the federal occupation – to say nothing of the outrageous, authoritarian government overreach – D.C. Mayor Muriel Bowser has signed an order outlining how the District will “continue to work with the U.S. Marshals Service, the FBI, U.S. Park Police, the Drug Enforcement Administration, [and] the Bureau of Alcohol, Tobacco, Firearms and Explosives,” according to WTOP. This report notes that, “Bowser's order provides a path for working with federal law enforcement…[a] public indication that federal law enforcement could remain in the city indefinitely.” Other D.C. officials, including the District's delegate in Congress Eleanor Holmes Norton, have decried the occupation. Unfortunately, Norton is not even afforded the power of a single vote in Congress. This debacle further underscores the necessity for sovereign statehood for D.C.* In more news of federal law enforcement overreach, Prem Thakker of Zeteo reports new figures that show, “61,226 people are currently in ICE detention — the highest number ever in US history.” Thakker goes on to report that “According to ICE data, 70% of these people have no criminal conviction.” This unjustifiable mass detention shows no signs of slowing down, with ICE being granted larger and larger budgets and more and more latitude by the administration. The parallels to other shadowy secret police organizations throughout history continue to grow more pronounced.* Labor Notes editor Luis Feliz Leon reports Columbia University is seeking to bust graduate worker unions – at Columbia and beyond. A statement from the union reads “Over the summer, the university expelled and suspended 80 students, eliminated all but ten…graduate instructor jobs, and filed an Unfair Labor Practice Charge that could reshape the future of higher ed.” This marks yet another blow to the august reputation of Columbia, already damaged by their authoritarian overreaction to pro-Palestine protests and their capitulation to borderline extortion by Trump.* In the federal government, Trump continues to attack critical safety regulators. Reuters reports, “Two of the three remaining commissioners at the Nuclear Regulatory Commission, the U.S. nuclear safety watchdog, told a Senate hearing on Wednesday they feel President Donald Trump could fire them if they obstruct his goal to approve reactors faster.” Trump, via executive order, has committed the United States to, “fast-tracking new reactor licenses and quadrupling U.S. nuclear energy capacity by 2050…while also reducing staffing at the NRC.” The Commission is already down to just three members from its usual five and according to this report, “a dozen senior level managers…have left or announced they will leave since January, and…143 staff departed between January and June.” The Commission is currently considering five reactor applications and “expects another 25 to 30 soon.” Whatever one's thoughts are on nuclear energy in general, it is wildly irresponsible and dangerous to consider these reactor proposals by a commission short-staffed and constantly threatened with dismissal.* Finally, the Government Accountability Project has submitted a stunning whistleblower complaint on behalf of Chuck Borges, Chief Data Officer at the Social Security Administration. This complaint concerns “serious data security lapses, evidently orchestrated by DOGE officials, currently employed as SSA employees, that risk the security of over 300 million Americans' Social Security data…including apparent systemic data security violations, uninhibited administrative access to highly sensitive production environments, and potential violations of federal privacy laws by DOGE personnel.” The most critical violation is the DOGE staffers' move to “create a live copy of the country's Social Security information in a cloud environment that circumvents oversight.” As this complaint explains, “This vulnerable cloud environment is effectively a live copy of the entire country's Social Security information…that…lacks any security oversight from SSA or tracking to determine who is accessing or has accessed the copy of this data.” This includes “all data submitted in an application for a United States Social Security card—including the name of the applicant, place and date of birth, citizenship, race and ethnicity, parents' names and social security numbers, phone number, address, and other personal information.” If this data were to be compromised – as is eminently possible given the unsecured and unsupervised nature of the cloud copy, “Americans may be susceptible to widespread identity theft, may lose vital healthcare and food benefits, and the government may be responsible for re-issuing every American a new Social Security Number.” This staggering degree of carelessness and incompetence is almost unbelievable, if not for the fact that it comports perfectly with the DOGE track record. We can only hope lawmakers and regulators take swift action to shut down this ticking timebomb of data before it's too late.This has been Francesco DeSantis, with In Case You Haven't Heard. Get full access to Ralph Nader Radio Hour at www.ralphnaderradiohour.com/subscribe

A poche ore dai festeggiamenti per i 132 anni del Genoa, andiamo a vedere le notizie di casa Genoa. Buoncalcioatutti!

In questa puntata andiamo a riepilogare e approfondire i fatti di casa Genoa delle ultime 48 ore, con un passaggio dettagliato sugli appuntamenti del weekend e sui nazionali che scenderanno in campo oggi. Buoncalcioatutti!

Il Genoa torna ad allenarsi con ben undici giocatori in meno partiti per le nazionali. Andiamo a vedere in puntata chi è rimasto a Pegli, quali saranno gli impegni dei nazionali e quali sono le possibili date di rientro in vista di Como-Genoa. Buoncalcioatutti!

Inter stunned by Udinese, Milan bounce back at Lecce, Cremonese edge Sassuolo in late drama, Lazio hit four past Verona and Juve rely on Vlahovic again at Genoa. We're joined by Craig from Calcio Corner to break down all the action, key talking points, and what it means after Gameweek 2. If you want to support The Anglo Italian Podcast and get every episode, simply become a member on Patreon.com/TheAngloItalianPodcast and become our Calcio-Only fans for only £2 a month. All starting from the 1st September. Follow us on: ⁠Twitter⁠, ⁠Instagram⁠, ⁠YouTube⁠ and ⁠Tiktok Learn more about your ad choices. Visit podcastchoices.com/adchoices

Il calciomercato estivo 2025 si è chiuso e si è chiusa anche la sessione del Genoa. Abbiamo provato a ripercorrere quelle che sono state le mosse del club, tra pochi investimenti immediati, tanti diritti e obblighi di riscatto e la scelta di investire sulle giovanili e sfoltire ulteriormente la rosa. Ne parliamo in puntata. Buoncalcioatutti!

Juventus recorded their straight win to open the 2025-26 season on Sunday, with the game-winning goal scorer being the same striker we expected to have been sold by now. Except, he's still here and now proving to be important again. 0:00 Introduction 02:22 Takeaways from the week that was 08:18 General thoughts on Genoa 0-1 Juventus 22:16 Vlahovic being decisive again 33:17 Last day of Mercato Madness with Zhegrova In, and Nico Out 47:18 Selling Savona to Nottingham Forest 52:42 Social Media Questions You can follow us — or send us questions — on Bluesky ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@bwrao.bsky.social⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, Twitter ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@JuventusNation⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠on Facebook⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ as well as the Fans First Sports Network ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@FansFirstSN⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on Twitter. You can also follow us on ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠our Instagram page⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠, too! Get all of our match coverage, transfer rumors and much more at our website, ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠blackwhitereadallover.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠. Learn more about your ad choices. Visit megaphone.fm/adchoices

Juventus pull off DEADLINE DAY MAGIC! ✨ Zhegrova and Openda arrive in Turin, with a new wingback signing also on the way! Did Comolli finally deliver what was expected from this mercato? Has Juventus now built a squad strong enough for Igor Tudor to chase the Scudetto?Plus, Juve get the job done against Genoa thanks to Dusan Vlahovic's impact off the bench—proving he can still be useful this season after all the transfer drama. We break down the transfers, the Genoa win, and what this means for Juve's season moving forward!

Con le 4 gare della domenica si chiude anche la 2a giornata di Serie A: impresa dell'Udinese che vince a San Siro contro l'Inter, Vlahović dalla panchina segna un gol da 3 punti a Genova, un super Castellanos trascina la Lazio che spazza via l'Hellas, pari a reti bianche tra Torino e Fiorentina. L'analisi a cura di Giuseppe Broggini e Simone Indovino.Potrero, dove tutto ha inizio. Un podcast sul calcio italiano e internazionale.Su Como TV (https://tv.comofootball.com) nel 2025 potete seguire in diretta e gratuitamente le partite della Saudi Pro League, Saudi King's Cup, Supercoppa d'Arabia, Copa Libertadores, Copa Sudamericana, Recopa, Liga Profesional Argentina, Trofeo de Campeones argentino, Eredivisie, Coppa di Francia, Scottish Premiership, Coppa di Scozia, Scottish League Cup, Scottish Championship, Coppa di Portogallo, Supercoppa di Portogallo, HNL croata e tutti i contenuti di calcio italiano e internazionale on demand.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/potrero--5761582/support.

Il commento dopo la partita di ieri tra Genoa e Juventus. I rossoblù perdono in casa contro i bianconeri e si affacciano alla sosta con un punto in due partite. Buoncalcioatutti!

L'asta del fantacalcio è alle porte! In questo secondo episodio - insieme a Daniele Del Basso di Fanta Passion - vi consigliamo chi prendere e chi evitare, esaminando Cremonese, Fiorentina, Genoa ed Hellas Verona. Conduce Andrea Di Giacomo.Potrero, dove tutto ha inizio. Un podcast sul calcio italiano e internazionale.Su Como TV (https://tv.comofootball.com) nel 2025 potete seguire in diretta e gratuitamente le partite della Saudi Pro League, Saudi King's Cup, Supercoppa d'Arabia, Copa Libertadores, Copa Sudamericana, Recopa, Liga Profesional Argentina, Trofeo de Campeones argentino, Eredivisie, Coppa di Francia, Scottish Premiership, Coppa di Scozia, Scottish League Cup, Scottish Championship, Coppa di Portogallo, Supercoppa di Portogallo, HNL croata e tutti i contenuti di calcio italiano e internazionale on demand.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/potrero--5761582/support.

Calcio d'agosto non ti conosco, recita un vecchio detto pallonaro. Siamo d'accordo, ma, comunque queste prime due giornate di campionato ci hanno dato segnali significativi, tra continuità e novità.

Kyle tells Claire he kissed Audra, then prepares to propose!; A new war between Jack and Victor; Tristan Rogers’ final appearance as Colin; Cane changes his plans, so Phyllis and Billy change their plans too. PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The Chatterbox” to Read YOUR Comments! Sign up […]

Apriamo la puntata con Gianni De Biasi per commentare un entusiasmante inizio di campionato, con tante incognite ancora da decifrare e qualche certezza già delineata.Tra queste c’è sicuramente il Napoli di Conte, che ieri, non senza difficoltà, ha piegato un ostico Cagliari grazie al gol nel finale di Anguissa. Sentiamo cosa ne pensa Enrico Fedele.Spazio poi al basket. L’Italia di Pozzecco supera in rimonta la Georgia 78-62 e si mette alle spalle la sconfitta con la Grecia. Stasera importante sfida contro la Bosnia Erzegovina. Ne parliamo con Davide Pessina che sta seguendo la competizione per Sky Sport.Torniamo al calcio. Juventus e Inter saranno in campo rispettivamente alle 18,30 contro il Genoa e alle 20,45 contro l’Udinese. Ci raccontano il clima prepartita Max Nerozzi e Marco Barzaghi.Mancano inoltre poco più di 24 ore alla chiusura del calciomercato. Con Gianluigi Longari di Sportitalia vediamo quali potrebbero essere gli affari dell’ultimo minuto.A seguire voliamo in Olanda, dove si è da poco conclusa la gara numero 15 del mondiale di Formula 1. Con Giorgio Terruzzi analizziamo la vittoria pesante di Piastri e il disastro delle Ferrari.Infine il tennis. Vincenzo Martucci ci porta nel cuore degli US OPEN. Ieri Sinner ha superato in rimonta il canadese Shapovalov e si prepara alla sfida di domani contro Bublik.

The Soccer Sharps betting show returns with more picks and predictions for the upcoming weekend in European football. This week our co-host and soccer handicapper, Jordan Crittenden, is joined by football betting expert Nick Dianni to discuss key matches taking place across the Premier League, La Liga, Bundesliga, and Serie A. The show delivers betting advice, predictions, and Official Plays. 00:00 Introduction & Last Week's Results 05:13 Liverpool vs Arsenal 11:09 Brighton vs Manchester City 15:23 Augsburg vs Bayern Munich 19:49 Girona vs Sevilla 24:07 Celta Vigo vs Villarreal 26:57 Genoa vs Juventus 30:30 Official Plays Thank you for listening and watching! Get more from Nick Dianni ( @nickdianni ) at the Kicks and Picks Podcast( https://www.youtube.com/@KicksandPicksPodcastand ) and The Plus Money Podcast ( https://www.youtube.com/@theplusmoneypod ). JOIN OUR DISCORD SERVER: https://discord.gg/cx7WJKWabQ SUBSCRIBE ON YOUTUBE: https://www.youtube.com/@thesoccersharps VIEW OUR P&L SPEADSHEETS: https://drive.google.com/drive/folders/1jca0dVIW7FumZ27VEcyhdre0Ke5gh7C6?usp=sharing  EMAIL US:  azsoccersharps@gmail.com  FOLLOW US: X: @TheSoccerSharps Instagram: @TheSoccerSharps TikTok: thesoccersharps Bluesky: @thesoccersharps.bsky.social The Soccer Sharps podcast is a part of The Hooligan Soccer Network. https://hooligan-soccer.com/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Le ultime in vista di Genoa-Juventus dopo la conferenza di oggi di mister Vieira: dalle scelte al mercato, mentre in uscita si avvicinano le cessioni di quattro elementi rossoblù. Intanto, aumentano i calciatori del Grifone convocati in nazionale. Buoncalcioatutti!

Host Davide Soldato and guest Dr. John K. Lin discuss the JCO article "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-For-Service Beneficiaries with Metastatic Breast, Colorectal, Lung, and Prostate Cancer." TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato: Hello, and welcome to JCO After Hours, the podcast where we sit down with authors of the latest articles published in the Journal of Clinical Oncology. I'm your host, Dr. Davide Soldato, a medical oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by Dr. Lin, assistant professor in the Department of Health Services Research at the University of Texas MD Anderson Cancer Center. Dr. Lin and I will be discussing the article titled, "Racial and Ethnic Disparities Along the Treatment Cascade Among  Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." Thank you for speaking with us, Dr. Lin. Dr. Lin: Thank you so much for having me. I appreciate it. Dr. Davide Soldato: So, just to start, to frame a little bit the study, I just wanted to ask you what prompted you and your team to look specifically at this question - so, racial and ethnic disparities within this specific population? And related to this question, I just wanted to ask how this work is different or builds on previous work that has been done on this research topic. Dr. Lin: Yeah, absolutely. Part of the impetus for this study was the observation that despite people who are black or Hispanic having equivalent health insurance status - they all have  Medicare Fee-for-Service - we've known that treatment and survival differences and disparities have persisted over time for patients with metastatic breast, colorectal, lung, and prostate cancer. And so, the question that we had was, "Why is this happening, and what can we do about it?" One of the reasons why eliminating racial and ethnic disparities in survival among Medicare beneficiaries with metastatic cancer has been elusive is because these disparities are occurring along a lot of dimensions. Whether or not it's because the patient presented late and has very extensive metastatic cancer; whether or not the patient has had a difficult time even seeing an oncologist; whether or not the patient has had a difficult time starting on any systemic therapy; or maybe it's because the patient has had a difficult time getting guideline-concordant systemic therapy because, more recently, these treatments have become so expensive. Disparities, we know, are occurring along all of these different facets and areas of the treatment cascade. Understanding which one of these is the most important is the key to helping us alleviate these disparities. And so, one of our goals was to evaluate disparities along the entire treatment cascade to try to identify which disparities are most important. Dr. Davide Soldato: Thank you very much. That was very clear. So, basically, one of the most important parts of the research that you have performed is really focusing on the entire treatment cascade. So, basically, starting from the moment of diagnosis up to the moment where there was the first line of treatment, if this line of treatment was given to the patient. So, I was wondering a little bit, because for this type of analysis, you used the SEER-Medicare linked database. So, can you tell us a little bit which was the period of time that you selected for the analysis? Why do you think that that was the most appropriate time to look at this specific question? And whether you feel like there is any potential limitation in using this type of database and how you handled this type of limitations? Dr. Lin: Yeah, absolutely. It's a great question. And I want to back up a little bit because I want to talk about the entire treatment cascade because I think that this is really important for our research and for future research. We weren't the first people to look at along the treatment cascade for a disease. Actually, this idea of looking along the treatment cascade was pioneered by HIV researchers and has been used for over a decade by people who study HIV. And there are a lot of parallels between HIV and cancer. One of them is that with HIV, there are so many areas along that entire treatment cascade that have to go right for somebody's treatment to go well. Patients have to be diagnosed early, they have to be given the right type of antiretrovirals, they have to be adherent to those antiretrovirals. And if you have a breakdown in any one of those areas, you're going to have disparities in care for these HIV patients. And so, HIV researchers have known this for a long time, and this has been a big cornerstone in the success of getting people with HIV the treatment that they need. And I think that this has a lot of parallels with cancer as well. And so, I am hoping that this study can serve as a model for future research to look along the entire treatment cascade for cancer because cancer is, similarly, one of these areas that requires multidisciplinary, complex medical care. And understanding where it is breaking down, I think, is crucial to us figuring out how we can reduce disparities. But for your question about the SEER-Medicare linked database, so we looked between 2016 and 2019. That was the most recent data that was available to us. And one of the reasons why we were excited to look at this is because there were some new treatments that were just released and FDA-approved around 2018, which we were able to study. And this included immunotherapy for non–small cell lung cancer, and then it also included androgen receptor pathway inhibitors, the second-generation ones, for prostate cancer. And the reason why this is important is because for some time, as we have developed these new therapies, there's been a lot of concern that there have been disparities in access to these novel therapies because of how expensive they are, particularly for the Medicare population. And so one of the reasons why we looked specifically at this time period was to understand whether or not, in more recent years, these novel therapies, people are having increasing disparities in them and whether or not increasing disparities in these more expensive, newer therapies is contributing to disparities in mortality. That being said, obviously, we're in 2025 and these data are by now six years old, and so there are additional therapies that are now available that weren't available in the past. But I think that, that being said, at least it's sort of a starting point for some of the more important therapies that have been introduced, at least for non–small cell lung cancer and prostate cancer. And the database, SEER-Medicare, is helpful because it uses the population cancer registry, which is the SEER registry cancer registry, linked to Medicare claims. So, any type of medical care that's billed through Medicare, which is going to basically be all of the medical care that these patients receive, for the most part, we're going to be able to see it. And so, I think that this is a really powerful database which has been used in a lot of research to understand what kind of care is being received that has been billed through Medicare. So, one of the limitations with this database is if there is care that's received that was not billed through Medicare, we're not going to be able to see that. And this does not happen probably that frequently, particularly because most patients who have insurance are going to be receiving care through insurance. However, we may see it for some of the oral Part D drugs. Some of those drugs are so expensive that patients cannot pay for the coinsurance during that time. And it's possible that some of those drugs patients were getting for free through the manufacturer. We potentially missed some of that. Dr. Davide Soldato: So, going a little bit into the results, I think that these are very, very interesting. And probably the most striking one is that when we look at the receipt of any type of treatment for metastatic breast, colorectal, prostate, and lung cancer - and specifically when we look at guideline-directed first-line treatments - you observed striking differences. So, I just wanted you to guide us a little bit through the results and tell us a little bit which of the numbers surprised you the most. Dr. Lin: So, what we were expecting is to see large disparities in receiving what we called guideline-directed systemic therapy. And guideline-directed systemic therapy during this time kind of depended on the cancer. So, we thought that we were going to see large disparities in guideline-directed therapy because these were the more novel therapies that were approved, and thus they were going to be the more expensive therapies. And so, what this meant was for colorectal cancer, this was going to be any 5-FU–based therapy. For lung cancer, this was going to be any checkpoint inhibitor–based therapy. For prostate cancer, this was going to be any ARPI, so this was going to be things like abiraterone or enzalutamide. And for breast cancer, this was going to be CDK4 and 6 TKIs plus any aromatase inhibitor. And so, for instance, for breast, prostate, and lung cancer, these were going to be including more expensive therapies. And so, what we expected to see was large disparities in receiving some of these more expensive, novel therapies. And we thought we were going to see fewer disparities in receiving some of the cheaper therapies, such as aromatase inhibitors, 5-FU, older platinum chemotherapies for lung cancer, and ADT for prostate cancer. We were shocked to find that we saw large racial and ethnic disparities in seeing some of the older, cheaper chemotherapies and hormonal therapies. So for instance, for breast cancer, 59% of black patients received systemic therapy, whereas 68% of white patients received systemic therapy. For colorectal, only 23% of black patients received any systemic therapy versus 34% of white patients. For lung, only 26% of black patients received any therapy, whereas 39% of white patients did. And for prostate, only 56% of black patients received any systemic therapy versus 77% of white patients. And so, we were pretty shocked by how large the disparities were in receiving these cheap, easy-to-access systemic therapies. Dr. Davide Soldato: Thank you very much. So, I just wanted to go a little bit deeper in the results because, as you said, there were striking differences even when we looked at very old and also cheap treatments that, for the majority of the patients that were included inside of your study, were actually basically available for a very small price to these patients who had the eligibility for Medicare or Medicaid. And I think that one of the very interesting parts of the research was actually the attention that you had at looking how much of these disparities could be explained by several factors. And actually, one of the most interesting results is that you observed that low-income subsidy status was actually a big determinant of these disparities in terms of treatment. So, I just wanted to guide us a little bit through these results and then just your opinion about how these results should be interpreted by policymakers. Dr. Lin: Yeah, absolutely. I'm going to explain a little bit about what low-income subsidy status is and dual-eligibility status. Some of the listeners may not know what low-income subsidy status or dual-eligibility status is. Low-income subsidy status is part of Medicare Part D. Medicare Part D is an insurance benefit that allows patients to receive oral drugs. So these are drugs that are dispensed through the pharmacy, such as the CDK4/6 inhibitors, as well as second-generation ARPIs in our study. For patients who have Medicare Part D and whose income is low enough - falls below a certain federal poverty level threshold - those patients will receive their oral drugs for much cheaper. And this is really important for some of these more novel therapies because for some of these more novel therapies, if you don't have low-income subsidy status, you may be paying thousands of dollars for a single prescription of those drugs. Whereas if you have low-income subsidy status, you may be paying less than $10. And so that difference, greater than $1,000 or $2,000 versus less than $10, one would think that the patient who's paying less than $10 would be much more likely to receive those therapies. So that's low-income subsidy status. Low-income subsidy status, importantly, doesn't apply for infused medications like immunotherapy. But it's important to know that most people with low-income subsidy status - about 88% - are also dual-eligible. What dual-eligible means is that they have both Medicare and Medicaid. Medicare being the insurance that everybody has in our study who's greater than 65. And Medicaid is the state-run but federally subsidized insurance that patients with low incomes have. And so patients who are dual-eligible - and about 87% of those with low-income subsidy status are dual-eligible - those patients have both Medicaid and Medicare, and they basically pay next to nothing for any of their medical care. And that's because Medicare will reimburse most of the medical care and the copays or coinsurance are going to be covered by Medicaid. So Medicaid is going to pick up the rest of the bill. So, most of the patients who have low-income subsidy status who are dual-eligible, these patients pay almost nothing for their medical care - Part B or Part D, any of their drugs. And so, one would expect that if cost were the main determinant of disparities in cancer care, then one would expect that dual-eligibles, most of them would be receiving treatment because they're facing minimal to no costs. What we found is that when we broke down the racial and ethnic disparity by a number of factors - including LIS status/dual eligibility, age, the number of comorbidities, etcetera - what we found was that the LIS or dual-eligibility status explained about 20% to 45% of the disparities that we saw in receiving treatment. And what that means is despite these patients paying next to nothing for their drugs, these are the most likely patients to not be treated for their cancer at all. So they're most likely to basically be diagnosed, survive for two months, see an oncologist, and then never receive any systemic therapy for their cancer. And this is not just chemotherapies for colorectal or lung cancer. This includes cheaper, easier-to-tolerate hormonal therapies that you can just take at home for breast cancer, or you can get every six months for prostate cancer, that people who even have poorer functional status are able to take. However, for whatever reason, these dual-eligible or LIS patients are very unlikely to receive treatment compared to any other patient. The low likelihood of treating this group of patients, that explains a large portion of the racial and ethnic disparities that we see. Dr. Davide Soldato: And one thing that I think is very interesting and might be of potential interest to our listeners is, did you compare survival outcomes in these different settings? And did you observe any significant differences in terms of racial and ethnic disparities once you saw that there was a significant difference when looking at both receipt of any type of treatment and also guideline-directed treatments? Dr. Lin: We saw that there were large disparities in survival by race and ethnicity when you look overall. However, when you just account for the patients who received any systemic therapy at all - not just guideline-directed systemic therapy - those differences in survival essentially disappeared. And so, what that suggests is that if black patients were just as likely to receive any systemic therapy at all as white patients, we would expect that the survival differences that we were seeing would disappear. And this is not even just looking at guideline-directed systemic therapy. This was looking just at systemic therapy alone. And so, while guideline-directed systemic therapy should be a goal, our research suggests that if we are to close the gap in disparities in overall survival among black and white patients, we must first focus on patients just receiving any type of treatment at all. And that should be the very first focus that policymakers, that leaders in ASCO, that health system leaders, that physicians, that we should focus on: just trying to get any type of treatment to our patients who are poorer or black. Dr. Davide Soldato: Thank you very much. And this was not directly related to the research that you performed, but going back to this very point - so, increasing the number of patients that receive any kind of systemic treatment before looking at guideline-directed treatments - what would you feel would be the best way to approach this in order to decrease the disparities? Would you look at interventions such as financial navigation or maybe improving referral pathways or providing maybe more culturally adapted information to the patients? Because in the end, what we see is disparities based on racial and ethnicity. We see that we can reduce these disparities if we get these patients to the treatment. But in the end, what would you feel is the best way to bring patients to these types of treatments? Dr. Lin: I think the most important thing is to understand that these disparities are not primarily happening because of the high cost of cancer treatment. These disparities are happening because of other social vulnerabilities that these patients are facing. And so these vulnerabilities could be a lot of things. It could be mistrust of the medical system. It could be fear of chemotherapy or other treatments. It could be difficulty taking time off of work. It could be any number of things. What we do know is when we've looked at the types of interventions that can help patients receive treatment, navigation is probably the most effective one. And the reason why I think that is because when patients don't receive treatment because of social vulnerability, I sort of look at social vulnerability like links in a chain. Any weakest link is going to result in the patient not receiving treatment. This may be because they have a hard time taking time off of work. This may be because they had a hard time getting transportation to their physician. It may be because they had an interaction with a physician, but that interaction was challenging for the patient. Maybe they mistrusted the physician. Maybe they're worried about the medical system. If any of these things goes wrong, the patient is not going to be treated. The patient navigator is the only person who can spot any of those weak links within the chain and address them. And so, I think that the first thing to do is to get patient navigation systems in place for our vulnerable patients throughout the United States. And this is incredibly important because in Medicare, patient navigation is reimbursable. And so this is not something that's ‘pie in the sky'. This is something that's achievable today. The second thing is that it's really important that we see these vulnerabilities happening for patients who are dual-eligible, who have both Medicare and Medicaid. One of the reasons why this is important is because there has been a lot of research outside of what we've done that has shown vulnerabilities for dual-eligible patients who have Medicare for a number of different diseases. And the reason why is because, although patients are supposed to have the benefits of both Medicare and Medicaid, usually these two insurances do not play nicely together. It creates a huge, bureaucratic, complex mess and maze that most of these patients are unable to navigate. And so many of these patients are unable to actually receive the full reimbursement from both Medicare and Medicaid that they should be getting because those two insurers are not communicating well. And so the second thing is that national cancer organizations need to be supporting policies and legislation that is already being discussed in Congress to revamp the dual-eligible system so that it facilitates these patients getting properly reimbursed for their care from both Medicare and Medicaid and these systems working together well. The third thing is that Medicaid itself has many benefits that can allow patients to receive care, like they have transportation benefits so that patients can get to and from their doctor's appointments with ease. And so I think this will be additionally very, very helpful for patients. The last thing is, you know, it's possible that future innovations such as telemedicine and tele-oncology and cancer care at home can also make it easier for some of these patients who may be working a lot to receive care. But what I would say is that our study should be a call for healthcare delivery researchers to start piloting interventions to be able to help these patients receive systemic therapy. And so what this could look like is trying to get that care navigation and implement that in clinics so that patients can be receiving the care that they need. Dr. Davide Soldato: Thank you very much. That was a very clear perspective on how we can tackle this issue. So, I just wanted to close with a sort of personal question. I was wondering what led you to work specifically in this research field that is very challenging, but I think it's particularly critical in healthcare systems like in the United States. Dr. Lin: Yeah, absolutely. One of the most important things for me as an oncologist and a researcher is being able to know that all patients in the United States - and obviously abroad - who have cancer should be able to receive the kind of care that they deserve. I don't think that patients, because their incomes are lower or because their skin looks a certain color or because they live in rural areas, these shouldn't be determinants of whether or not cancer patients are receiving the care that they need. We can develop and pioneer the very best treatments and breakthroughs in oncology, but if our patients are not receiving them - if only 20% of our patients with colon cancer or lung cancer are receiving any type of systemic therapy, who are black - this is a big problem. But this is something that I think that our system can tackle. We need to get these breakthroughs that we have in oncology to every single cancer patient in America and every single cancer patient in the world. I think this is a goal that all oncologists should have, and I think that this is something that, honestly, is achievable. I think that research is a powerful tool to give us a lens into understanding exactly why it is that certain patients are not getting the care that they deserve. And my goal is to continue to use research to shed light on why our system is not performing the way that we all want it to be. Dr. Davide Soldato: Circling back to your research, actually the manuscript that was published was supported by a Young Investigator Award by the American Society of Clinical Oncology. So, was this the first step of a more broad research, or do you have any further plans to go deeper in this topic? Dr. Lin: Yeah, absolutely. First, I want to thank the ASCO Young Investigator Award for funding this research because I think it's fair to say that this research would not have happened at all without the support of the ASCO YIA. And the fact that ASCO is doing as much as it can to support the future generation of cancer researchers is incredible. And it's a huge resource, and having it come at the time that it did is critical for so many of us. So I think that this is an unbelievable thing that ASCO does and continues to do with all of its partners. For me, yeah, this is definitely a stepping stone to further research.  Medicare Fee-for-Service is only one part of the population. I want to spread this research and extend it to patients who have other types of insurances, look at other types of policies, and also try to conduct some of the cancer care delivery research that's needed to try to pilot some interventions that can resolve this problem. So hopefully this is the first step in a broader series of studies that we can all do collectively to try to eliminate racial and ethnic disparities in cancer care and survival. Dr. Davide Soldato: So, I think that we've come at the end of this podcast. Thank you again, Dr. Lin, for joining us today. Dr. Lin: Thank you so much. It was a pleasure to be a part of this. Dr. Davide Soldato: So, we appreciate you sharing more on your JCO article, "Racial and Ethnic Disparities Along the Treatment Cascade Among Medicare Fee-for-Service Beneficiaries With Metastatic Breast, Colorectal, Lung, and Prostate Cancer." If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Nella puntata di oggi, in assenza di sostanziali novità di mercato sponda Genoa, ritorniamo sulla Badia di Sant'Andrea, che è diventata la sede del settore giovanile rossoblù e del Genoa Women. Parentesi finale su Frendup e le convocazioni in nazionale. Buoncalcioatutti! 

Il Genoa propone un'anteprima stampa della Badia di Sant'Andrea, che sarà la nuova sede di giovanili maschili e femminili ed è giò operativa. Parliamo dell'avanzamento dei lavori, di quel che sarà, dei prossimi passi e di ciò che potrà accadere sul mercato nelle ultime giornate. Buoncalcioatutti!

Jake and Matt are back for the new season of Serie A! Giving you the full rundown of every single match in of the first game week. They also touch up on some of their favourite goals of the week and highlight key moments of the week that caught their eye.Follow us on Instagram, TikTok, Twitter, and YouTube for the latest updates. Support the show on Patreon to join our Fantasy League - winner gets a free kit of their choice!00:00 - 04:22 - Intro04:22 - 10:13 - Goal of the Week10:13 - 21:43 - Sassuolo 0–2 Napoli21:43 - 39:50 - Milan 1–2 Cremonese39:50 - 50:59 - Roma 1–0 Bologna50:59 - 1:00:01 - Inter 5–0 Torino1:00:01 - 1:14:00 - Juventus 2–0 Parma1:14:00 - 1:32:02 - Como 2–0 Lazio1:32:02 - 1:33:18 - Atalanta 1–1 Pisa1:33:18 - 1:43:15 - Cagliari 1–1 Fiorentina1:43:15 - 1:49:31 - Udinese 1–1 Verona1:49:31 - 1:57:14 - Genoa 0–0 Lecce1:57:14 - 2:01:47 - Wisdom with the Wank2:01:47 OutroBecome a patreon: ⁦https://patreon.com/Serieaspotlight?⁩utm_medium=unknown&utm_source=join_link&utm_campaign=creators hare_creator&utm_content=copyLinkSpecial Shoutout to our Media Partners Benevo Bid - Check out their collection here; ⁦https://benevobid.com/⁩#acmilan #inter #juventus #torino #napoli #atalanta #bologna #fiorentina #roma #lazio #lecce #cagliari #udinese #monza #venezia #como #hellasverona #parma #empoli #genoa #football #soccer #footballpodcast #podcast PatreonYoutube: ⁦https://www.youtube.com/@serieaspotlight⁩Instagram: ⁦https://www.instagram.com/serieaspotlight/⁩Twitter: ⁦https://x.com/SerieASpotlight?⁩

Il Genoa torna ad allenarsi a Pegli in vista della Juventus nel giorno in cui torna in auge il nome di Maupay. Questa mattina l'ultimo saluto del mondo rossoblù a Sidio Corradi. Buoncalcioatutti!

La terra vicentina nel tempio del calcio genovese. Là dove il tifo pulsa sotto la Gradinata Nord e il tempo sembra scandito dal battito dei cuori rossoblù, ieri è accaduto qualcosa che ha superato il confine del pallone. Un gesto semplice, ma profondissimo: la terra vicentina del Monte Maggio è tornata a incontrare quella dello stadio Luigi Ferraris grazie allo storico locale, Manuel Grotto.

Claire busts Audra out to Nate!; Victor asks for Claire’s forgiveness; Cane’s kids say ‘Leave us alone, Billionaire Dad!; Phyllis’ Artificial Intelligence; Jack and Diane’s Italian Romance; and The Genoa City Match Game 2025! PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The Chatterbox” to Read YOUR Comments! Sign up to […]

Bentornato campionato. Dopo la lunga sosta estiva sono andate in scena le prime quattro partite della Serie A 2025-2026.

Matt and Fabry talk about New season coming up and Transfer Market, plus a preview of the match against Lecce for Matvh Day 1 of Seria A 2025/26

AC Milan, Juventus, Inter Milan, Roma, Lazio, Fiorentina, Napoli, Atalanta, Genoa, Parma, Udinese, Sassuolo, Torino, Cremonese, Pisa, Cagliari, Hellas Verona, Bologna, Lecce & Como: which Serie A club has the best and worst kits in the 2025/2026 season? Nima Tavallaey and Carlo Garganese debate, discuss and analyze. This is an extended clip from this week's free transfer deep dive episode of The Italian Football Podcast which is available on Spotify, Apple Podcasts and YouTube. To listen to this & all other full episodes of The Italian Football Podcast (and support the show), go to ⁠⁠⁠⁠Patreon.com/TIFP⁠⁠⁠⁠ OR now also available on ⁠⁠⁠⁠Spotify⁠⁠⁠⁠ OR ⁠⁠⁠⁠YouTube Memberships⁠⁠⁠⁠ and sign up. Your support makes The Italian Football Podcast possible. Follow us: ⁠⁠⁠⁠Twitter⁠⁠⁠⁠, ⁠⁠⁠⁠Facebook⁠⁠⁠⁠, ⁠⁠⁠⁠Instagram⁠⁠⁠⁠, ⁠⁠⁠⁠YouTube⁠, ⁠TikTok Learn more about your ad choices. Visit podcastchoices.com/adchoices

Continuing with The Gay Science, and beginning with book IV, "Sanctus Januarius". Here, we encounter some of the most famous aphorisms: For the New Year, Preparatory Men ("Live Dangerously!") and Excelsior. Exciting times!Episode art: View of Genoa under the Snow - Eugenio Olivari (1882-1917)

Lily makes a deal with Cane; Cane orders Jack’s lunch; Billy gets Newman Bro’d; Victoria goes back to work; Nick and Sharon almost kiss; Victor confronts Nikki about almost losing Chancellor; Audra kisses Kyle in front of Claire!; Victoria confronts Victor about his interference; Mariah stonewalls Sharon while Tessa and Daniel grow closer; Danny bonds […]

In this episode, host Jonathan Sackier is joined by Emanuele Angelucci, Director of Hematology and Cellular Therapies and Director of the Stem Cell Transplant and Cellular Therapies Program at the Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Ospedale Policlinico San Martino Hospital in Genoa, Italy.   Timestamps   00:00 – Introduction 02:14 – The future of stem cell transplantation 03:15 – What continues to drive Emanuele in his work 05:40 – Donation of haematopoietic stem cells 10:00 – Gene therapy for haemoglobinopathies 11:40 – Will stem cell transplantation remain central in treating thalassaemia and sickle cell disease? 14:14 – Emanuele's work on iron overload and toxicity 16:53 – Current landscape for haemoglobinopathies 22:11 – Key recommendations in the most recent clinical guidelines for haemoglobinopathies  25:00 – Promising developments on the horizon for patients with haemoglobinopathies  28:00 – Emanuele's key takeaways 

Are you on board the Cane train?; Lily considers going… under cover; Billy is: In with Cane, Out with Jill, Out with Cane, and In with Jack… while Phyllis is ready to hack!; Claire comes for Victor; and Audra comes for Kyle! PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The […]

Chance Chancellor is dead; Nate and Amy learn Damian is dead; Kyle learns Cole is dead; Nick and Sharon kiss; and Tessa’s guardian angels. PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The Chatterbox” to Read YOUR Comments! Sign up to receive private e-mail updates from me: https://www.yrchat.com/storylines Why not pick […]

In apertura uno sguardo al calciomercato con Niccolò Ceccarini. A seguire, con Carlo Pernat parliamo di quello che sta diventando il "caso Zangrillo": all'ex presidente del Genoa è stato, infatti, negato l'abbonamento annuale al Ferraris.Con Simone Barlaam commentiamo, invece, i mondiali di Singapore, dove Sara Curtis e Thomas Ceccon hanno scritto due pagine della storia del nuoto italiano: la prima gareggiando per la prima volta in assoluto in una finale 100 stile libero e il secondo migliorando il record italiano nei 100 farfalla.In chiusura, gli ottanta anni della Pallacanestro Varese con Flavio Vanetti.

Announcement! Please join other podcast listeners for the next online BGTG Mini-Con, scheduled for September 6. I plan to be online from 9am-9pm Pacific time, including Discord for voice & video. The games will mostly be played on BoardgameArena, but adventurous gamers can also use Yucata, Brettspielwelt, Boardgames.io, Steam, apps, or whatever. It's free, and no RSVP or signup is necessary. Opener: Qwinto Closer: The SdJ awards ceremony, which we watched/listened to live on the drive back from a convention Over the years you've heard me talk about a number of game conventions. Usually that's recounting the games I played, and my enthusiasm for them in a 5-star rating. This time, I'm taking more of a meta approach to the topic. Yes, I'm still talking about a convention I went to recently, and some games played there, but half of the episode is about the idea of game conventions in the first place. The different types, which ones I prefer, and so on. Then the second half was recorded at a recent convention, meant to highlight the sort of fun, deep, not-so-serious discussions about the hobby and our shared experience in it. That's a lot of what I enjoy about game conventions--getting to hang out for continuous time with others who are just as geeky as I am about boardgames. I'm among my people! In this particular case, DaveO, Jonathan, Jeff, and SteveV join me to talk about games of designer Rüdiger Dorn. We concentrated on those for an entire day. This prolific designer has titles from 1992 to the present day. He's won the Kennerspiel des Jahres and been nominated for the Spiel des Jahres multiple times. Some of his most famous titles include Istanbul, Goa, Jambo, Traders of Genoa, and Louis XIV...none of which we played! Instead we tabled Dragonheart, Las Vegas Royale, Emerald, Montana, Rune Stones, My Farm Shop, Karuba, Arkadia, Danger 13, Mercado, Karuba the Card Game, and Diamonds Club. That was primarily with two groups playing all day long on two tables. It was the Dornücopia! At the last minute I thought a funny hat would be a great addition to our little event. While I couldn't find a cornucopia hat on short notice, I did find a corn hat. That was great! The winner of a game was crowned with it, and soon enough we were calling that person The Great Dornholio. Now I think all of our future mini-events will benefit from a special hat!     -Mark

Nick gets sliced and salted!; Nikki prepares to trade Chancellor for her son’s freedom; The butler did it; Kyle trumps Audra; and Billy and Jack consider parting ways. PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The Chatterbox” to Read YOUR Comments! Sign up to receive private e-mail updates from me: […]

The timeline of Aaron Sorkin's THE NEWSROOM is getting further and further into the 2012 presidential election... so it only makes sense that Season 2 Episode 6 ("One Step Too Many") is the horniest episode yet! We catch up on some shocking developments in the "Genoa tip," and find out the true meaning of "discretionary time." PATREON-EXCLUSIVE EPISODE - https://www.patreon.com/posts/640-time-part-16-134860722

Paul Hawksbee was joined by Andy Jacobs for this afternoons podcast. Brooke Norton-Cuffy, Genoa and England U21 Euro winner, spoke pre-season football and Viktor Gyokeres. Martin Kaymer discussed Scottie Scheffler and Tiger Woods, and Tim Vickery joined us live in the studio to provide some transfer news. Enjoy ! Hosted on Acast. See acast.com/privacy for more information.

Let's continue our month of relaxing travels to sleep as we return to 19th century Italy with Charles Dickens and wind through the maze-like, mysterious, miasmatic, marvelous streets of Genoa. You can practically smell the place, which…was probably better avoided. Yikes. Help us stay ad-free and 100% listener supported! Patreon: https://www.patreon.com/boringbookspod Buy Me a Coffee: https://www.buymeacoffee.com/d5kcMsW   Read “Pictures from Italy” at Project Gutenberg: https://www.gutenberg.org/ebooks/650 Music: "Peace,” by Lee Rosevere, licensed under CC BY, https://leerosevere.bandcamp.com   If you'd like to suggest a copyright-free reading for soft-spoken relaxation to help you overcome insomnia, anxiety and other sleep issues, connect on our website, http://www.boringbookspod.com.

Damian is dead!; Whodunnit?; The usual suspects; and Audra and Kyle grieve appropriately… by kissing! PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The Chatterbox” to Read YOUR Comments! Sign up to receive private e-mail updates from me: https://www.yrchat.com/storylines Why not pick up a bonus Y&R Chat episode at: http://www.GenoaCitySoap.com I […]

Paolo Ardoino is the CEO of Tether, the company behind the ticker symbol USDT, the world's largest stablecoin. He also serves as CTO of the cryptocurrency exchange Bitfinex and co-founded Holepunch, a platform for peer-to-peer applications. Ardoino holds a Master's in Computer Science from the University of Genoa and is one of the most visible proponents of improving the banking system with cryptocurrencies.In this conversation, we discuss:How Paolo built the infrastructure behind the world's most used stablecoin and why he believes math, not politics, should govern moneyWhy he believes Bitcoin is the first form of money governed by math, and how that math could reshape global financeHow USDT became the most used digital dollar by solving practical challenges in regions with limited banking accessWhy Paolo believes traditional finance is broken and how decentralized tech offers a more inclusive infrastructureThe case for brain–computer interfaces and why Paolo sees human and AI symbiosis as the next frontier of intelligenceWhy he's optimistic about AI's role in society, even as he argues that long term AI safety might be an illusionResources:Subscribe to the AI & The Future of Work NewsletterConnect with Paolo on LinkedIn or on XAI fun fact articleOn How to Ensure the AI and Workplace Technologies Align with Civil Rights Laws 

Count Cane; Lily’s Dream; Kyle sniffs Audra; Phyllis hedges her bets; Jack explodes on Billy; Sympathy for Sally; Mariah smothered that guy; and Danny proposes to Christine! PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The Chatterbox” to Read YOUR Comments! Sign up to receive private e-mail updates from me: https://www.yrchat.com/storylines […]

ITALY: CHRISTOPHER COLUMBUS IN THE REPUBLIC OF GENOA'S ZOAGLI 1900 COLUMBIS 0HI0

Cole’s untimely death; Cane is the Monopoly Man; Adam boards the train; Chelsea spots Holden’s con; Billy signs Abbott Comm over to Sally (sorta); Amanda creepily defends Cane; and Damian puts Audra on notice! PLUS: The Weekly Y&R Chat Poll, “Who Said It” Game, and Opening “The Chatterbox” to Read YOUR Comments! Sign up to […]